Document Detail


Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure.
MedLine Citation:
PMID:  20385972     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Scavenging of the vasodilator nitric oxide by myeloperoxidase activity in the vasculature may contribute to hypertension. Because hydrogen peroxide is a cosubstrate of myeloperoxidase, hyperglycemia-induced oxidative stress may strengthen the relationship between myeloperoxidase and blood pressure. We investigated this relationship and its modification by hyperglycemia and oxidative stress in a population-based cohort of elderly subjects with normal glucose metabolism (n=267), impaired glucose metabolism (n=189), and type 2 diabetes (n=290). In an age- and sex-adjusted linear regression model, plasma myeloperoxidase was positively associated with systolic blood pressure (2.10 mm Hg per 1 SD increment of myeloperoxidase [95% CI: 0.66 to 3.54]), and this association was stronger at higher levels of fasting glucose (0.61 [-1.70 to 2.93], 1.33 [-1.43 to 4.10], and 3.42 [1.01 to 5.82] for increasing tertiles of glucose) and higher plasma levels of oxidized low-density lipoprotein (0.92 [-1.31 to 3.14], 2.00 [-0.71 to 4.70], and 3.58 [0.98 to 6.19] for increasing tertiles of oxidized low-density lipoprotein). Likewise, the relationship between myeloperoxidase and blood pressure was strongest under conditions associated with oxidative stress, like obesity, low high-density lipoprotein cholesterol, metabolic syndrome, and type 2 diabetes. The strength of these associations was only marginally attenuated by adjustment for other cardiovascular risk factors. Our data demonstrate that myeloperoxidase is positively and independently associated with blood pressure, and this association is strongest in subjects with (hyperglycemia-induced) oxidative stress. These observations, together with emerging evidence that myeloperoxidase-derived oxidants contribute to the initiation and propagation of cardiovascular disease, identify myeloperoxidase as a promising target for drug development.
Authors:
Leonard P Van der Zwan; Peter G Scheffer; Jacqueline M Dekker; Coen D A Stehouwer; Robert J Heine; Tom Teerlink
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-04-12
Journal Detail:
Title:  Hypertension     Volume:  55     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-20     Completed Date:  2010-06-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1366-72     Citation Subset:  IM    
Affiliation:
Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Biological Markers / blood
Blood Glucose / metabolism
Blood Pressure / physiology
Blood Pressure Determination
Cardiovascular Diseases / physiopathology,  prevention & control
Cohort Studies
Diabetes Mellitus, Type 2 / blood,  diagnosis,  epidemiology*
Female
Humans
Hyperglycemia / blood,  diagnosis,  epidemiology*
Hypertension / blood,  diagnosis,  epidemiology*
Linear Models
Male
Multivariate Analysis
Oxidative Stress / physiology*
Peroxidase / blood*,  metabolism
Probability
Prognosis
Proportional Hazards Models
Reference Values
Risk Assessment
Severity of Illness Index
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Blood Glucose; EC 1.11.1.7/Peroxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children a...
Next Document:  Ribonucleic acid interference knockdown of interleukin 6 attenuates cold-induced hypertension.